著者

Holly Beanlands

出版者

Japanese Society of Nuclear Cardiology

雑誌

Annals of Nuclear Cardiology (ISSN:21893926)

巻号頁・発行日

vol.3, no.1, pp.61-65, 2017 (Released:2017-10-31)

参考文献数

10

被引用文献数

1 3

---

When you have finally completed your research, documented your findings, observations, conclusions and future considerations, the time has come to add your work to that of the larger nuclear cardiology community. But how can you share your work with other scientists? For a young physician new to the world of publishing, the task of putting together an illuminating, cohesive and yet succinct manuscript can appear daunting. Even so, the “publish or perish” imperative remains if you are to advance your career while contributing to the worldwide pool of knowledge, so try you must. Luckily, there are some concrete principles you can follow that will remove some of the mystery and, from an editorial point of view, improve your chances of having your manuscript accepted for submission. Presenting findings in a way that has the best possible chance of being accepted for publication means paying close attention to clarity, accuracy and suitability of both content, in terms of science, and presentation, in terms of language, style and format. This review will address the role that editing plays in the submission and publication process and will provide some practical approaches for improving your manuscript.

著者

Fumio Terasaki Keiichiro Yoshinaga

出版者

Japanese Society of Nuclear Cardiology

雑誌

Annals of Nuclear Cardiology (ISSN:21893926)

巻号頁・発行日

vol.3, no.1, pp.42-45, 2017 (Released:2017-10-31)

参考文献数

6

被引用文献数

77 138

---

In recent years, advancements in diagnostic imaging modalities, such as cardiac magnetic resonance (CMR) and 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET), as well as the accumulation of cases, have allowed a more accurate diagnosis of cardiac sarcoidosis (CS). In addition, emerging cases of “isolated CS” in which no obvious lesions are present in organs other than the heart have been reported, and the clinical importance of CS has become recognized. Many issues including etiology, pathology, diagnosis, and treatment of CS remain to be solved. Considering this situation, guidelines for the diagnosis and treatment of cardiac sarcoidosis were recently updated by the Japanese Circulation Society and were published in February 2017.

著者

João V. Vitola Maurizio Dondi Pedro Prado Leslee Shaw Diana Paez

出版者

Japanese Society of Nuclear Cardiology

雑誌

Annals of Nuclear Cardiology (ISSN:21893926)

巻号頁・発行日

vol.5, no.1, pp.44-46, 2019 (Released:2019-08-31)

参考文献数

6

被引用文献数

3 7

---

Hybrid imaging using PET/CT have various applications in cardiology. Anatomy, physiology or both can be evaluated. Routine attenuation correction can be performed and improve accuracy for nuclear cardiology studies. The extent of availability and utilization of hybrid imaging technology worldwide is currently unknown. The International Atomic Energy Agency (IAEA) in cooperation with QUANTA performed a web-based survey among physicians working with nuclear imaging to evaluate the current availability of hybrid imaging and its use for nuclear cardiology (NC). Contact e mails of physicians working in the field of nuclear cardiology were available from a data base at the human health department of the IAEA in Vienna, Austria and an international network of nuclear cardiologist at QUANTA in Curitiba, Brazil. Data from 80 countries in both high-income countries (HIC, n=16) and low-and-middle income countries (LMIC, n=64) representing all world regions, was obtained. At the country level, PET/CT is available in all world regions being widely available in North and Latin America, Europe, Asia and Oceania with a heterogeneous availability in Africa. Nevertheless, only 22.4% of centers in HIC and 10.9% in LMIC that have PET/CT available use it for NC applications. These data will help us to work with scientific societies and institutions to design strategies to diffuse information for physicians so they can take full advantage of PET/CT technology to obtain additional information that could impact patient care.

著者

Shinichiro Kumita Keiichiro Yoshinaga Masao Miyagawa Mitsuru Momose Keisuke Kiso Tokuo Kasai Masanao Naya

出版者

Japanese Society of Nuclear Cardiology

雑誌

Annals of Nuclear Cardiology (ISSN:21893926)

巻号頁・発行日

vol.5, no.1, pp.141-159, 2019 (Released:2019-08-31)

参考文献数

96

被引用文献数

2

著者

Osamu Manabe Masanao Naya Keiichiro Yoshinaga Noriko Oyama-Manabe Hiroshi Ohira Tadao Aikawa Nagara Tamaki

出版者

Japanese Society of Nuclear Cardiology

雑誌

Annals of Nuclear Cardiology (ISSN:21893926)

巻号頁・発行日

vol.3, no.1, pp.205-209, 2017 (Released:2017-10-31)

参考文献数

25

被引用文献数

1

---

Cardiac positron emission tomography (PET) has evolved over the several decades since its introduction. In current clinical practice and research, cardiac PET imaging is accepted as a valuable noninvasive modality for assessing various cardiac diseases such as coronary artery disease (CAD), cardiac tumors, and inflammatory diseases including cardiac sarcoidosis (CS). PET enables the imaging and evaluation of the cardiovascular system by myocardial perfusion with 82Rb, 13N-NH3 and 15O-H2O, and those of metabolism and inflammation using 18F-fluorodeoxyglucose (18F-FDG). PET has demonstrated superior diagnostic accuracy for the detection of CAD and also has well-established prognostic value. The combination of qualitative and absolute quantifications of myocardial blood flow enhances the diagnostic accuracy for multiple-vessel disease and provides incremental functional and prognostic information. In this review, we focus on the current and future roles of cardiac PET imaging, on the basis of our own experience.

著者

Emi Tateishi Keisuke Kiso

出版者

Japanese Society of Nuclear Cardiology

雑誌

Annals of Nuclear Cardiology (ISSN:21893926)

巻号頁・発行日

vol.4, no.1, pp.151-154, 2018 (Released:2018-08-31)

参考文献数

6

---

Since cardiac sarcoidosis (CS) portends adverse outcomes, early diagnosis of active inflammation in CS is essential for therapeutic and prognostic advantages. 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) has been used for the clinical evaluation of active inflammatory lesions in CS. While myocardium can utilize both free fatty acids and glucose as the substrates of energy metabolism, the physiological myocardial 18F-FDG uptake often makes it difficult to detect the pathological 18F-FDG accumulation. Prolonged fasting and low-carbohydrate diet are most commonly used for suppressing physiological myocardial 18F-FDG uptake, and moreover unfractionated heparin administration is sometimes considered. Sufficient preparation allows for the establishment of increased 18F-FDG uptake in myocardium as active inflammatory lesions. Typical patterns of pathological 18F-FDG accumulation in myocardium are “focal” and “focal-on-diffuse” and these are often corresponded with myocardial perfusion abnormality. In case with inconclusive 18F-FDG uptake, the simultaneous interpretation with myocardial perfusion imaging is useful and helpful to evaluate clinically significant 18F-FDG uptake in CS.